Explogen and German company MyBiotech have signed the cooperation agreement launching joint efforts in antibiotic discovery and development. MyBiotech has broad knowledge and expertise in biotechnological development and production of natural compounds, which covers all aspects of upstream and downstream processes. Explogen will provide the complementary expertise in metabolic engineering of microorganisms, development of activity-oriented screening approaches, cloning and manipulating large DNA fragments, genome sequencing and bioinformatics.  The agreement between Explogen and MyBiotech establishes the cooperative Platform that will facilitate new drug discovery and development and thus will contribute to addressing the global antibiotic resistance crisis. The main goal of such cooperation is to provide new chemical entities with well-established and optimized production process as potential candidates for further development into pharmaceutical leads.